KRAS and cancer: Despite the promising clinical outcome of these inhibitors, they are specific to the K-RasG12C mutant, which is found in ∼3% of pancreatic, ∼4% of colorectal, and ∼13% of lung cancers that harbor any oncogenic mutations in K-Ras (Cox et al., 2014; Prior et al., 2020), suggesting that these inhibitors would be suitable only for a small portion of cancer patients with the oncogenic mutant K-Ras.